The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Gene Review

Gvhd1  -  graft-versus-host disease 1

Mus musculus

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Gvhd1


Psychiatry related information on Gvhd1

  • Whole body images of anesthetized mice taken at various time points after cell infusion revealed the early migration of allogeneic cells to peripheral lymphoid organs, with later infiltration of GVHD target organs [6].
  • RAPA-treated mice had no clinical (e.g., weight loss, diarrhea, lethargy) or histologic evidence of classical acute or chronic GVHD but did develop a clinical-pathological syndrome consisting of ulcerative dermatitis, bile duct proliferation, and a nondestructive peribronchiolar pulmonary infiltration [7].
  • This association was still valid after correcting for other known variables (recipient age, donor-recipient gender relation, type of donor, conditioning regimen, diagnosis, stem cell source and GvHD prophylaxis) by logistic regression (OD=0.391, p=0.023) [8].

High impact information on Gvhd1


Chemical compound and disease context of Gvhd1


Biological context of Gvhd1


Anatomical context of Gvhd1


Associations of Gvhd1 with chemical compounds


Regulatory relationships of Gvhd1


Other interactions of Gvhd1


Analytical, diagnostic and therapeutic context of Gvhd1


  1. Genetics of graft-versus-host disease, I. A locus on chromosome 1 influences development of acute graft-versus-host disease in a major histocompatibility complex mismatched murine model. Allen, R.D., Dobkins, J.A., Harper, J.M., Slayback, D.L. Immunology (1999) [Pubmed]
  2. Graft-versus-host disease and severe combined immunodeficiency. Seemayer, T.A., Bolande, R.P., Lapp, W.S. N. Engl. J. Med. (1983) [Pubmed]
  3. Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Gao, E.K., Lo, D., Cheney, R., Kanagawa, O., Sprent, J. Nature (1988) [Pubmed]
  4. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Sykes, M., Szot, G.L., Swenson, K.A., Pearson, D.A. Nat. Med. (1997) [Pubmed]
  5. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Edinger, M., Hoffmann, P., Ermann, J., Drago, K., Fathman, C.G., Strober, S., Negrin, R.S. Nat. Med. (2003) [Pubmed]
  6. In vivo imaging of graft-versus-host-disease in mice. Panoskaltsis-Mortari, A., Price, A., Hermanson, J.R., Taras, E., Lees, C., Serody, J.S., Blazar, B.R. Blood (2004) [Pubmed]
  7. In vivo inhibition of cytokine responsiveness and graft-versus-host disease mortality by rapamycin leads to a clinical-pathological syndrome discrete from that observed with cyclosporin A. Blazar, B.R., Taylor, P.A., Panoskaltsis-Mortari, A., Sehgal, S., Vallera, D.A. Blood (1996) [Pubmed]
  8. CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bogunia-Kubik, K., Duda, D., Suchnicki, K., Lange, A. Haematologica (2006) [Pubmed]
  9. Host-reactive CD8+ memory stem cells in graft-versus-host disease. Zhang, Y., Joe, G., Hexner, E., Zhu, J., Emerson, S.G. Nat. Med. (2005) [Pubmed]
  10. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Reddy, P., Maeda, Y., Liu, C., Krijanovski, O.I., Korngold, R., Ferrara, J.L. Nat. Med. (2005) [Pubmed]
  11. Donor APCs are required for maximal GVHD but not for GVL. Matte, C.C., Liu, J., Cormier, J., Anderson, B.E., Athanasiadis, I., Jain, D., McNiff, J., Shlomchik, W.D. Nat. Med. (2004) [Pubmed]
  12. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Merad, M., Hoffmann, P., Ranheim, E., Slaymaker, S., Manz, M.G., Lira, S.A., Charo, I., Cook, D.N., Weissman, I.L., Strober, S., Engleman, E.G. Nat. Med. (2004) [Pubmed]
  13. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. Kim, Y.M., Sachs, T., Asavaroengchai, W., Bronson, R., Sykes, M. J. Clin. Invest. (2003) [Pubmed]
  14. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Xun, C.Q., Thompson, J.S., Jennings, C.D., Brown, S.A., Widmer, M.B. Blood (1994) [Pubmed]
  15. Selective T-cell subset ablation demonstrates a role for T1 and T2 cells in ongoing acute graft-versus-host disease: a model system for the reversal of disease. Liu, J., Anderson, B.E., Robert, M.E., McNiff, J.M., Emerson, S.G., Shlomchik, W.D., Shlomchik, M.J. Blood (2001) [Pubmed]
  16. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Cooke, K.R., Kobzik, L., Martin, T.R., Brewer, J., Delmonte, J., Crawford, J.M., Ferrara, J.L. Blood (1996) [Pubmed]
  17. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Sun, K., Wilkins, D.E., Anver, M.R., Sayers, T.J., Panoskaltsis-Mortari, A., Blazar, B.R., Welniak, L.A., Murphy, W.J. Blood (2005) [Pubmed]
  18. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Bachar-Lustig, E., Rachamim, N., Li, H.W., Lan, F., Reisner, Y. Nat. Med. (1995) [Pubmed]
  19. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Tamada, K., Shimozaki, K., Chapoval, A.I., Zhu, G., Sica, G., Flies, D., Boone, T., Hsu, H., Fu, Y.X., Nagata, S., Ni, J., Chen, L. Nat. Med. (2000) [Pubmed]
  20. Exacerbated graft-versus-host disease in Pirb-/- mice. Nakamura, A., Kobayashi, E., Takai, T. Nat. Immunol. (2004) [Pubmed]
  21. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Cobbold, S.P., Martin, G., Qin, S., Waldmann, H. Nature (1986) [Pubmed]
  22. Characterization of a newly discovered T-cell receptor beta-chain heterodimer expressed on a CD8+ bone marrow subpopulation that promotes allogeneic stem cell engraftment. Schuchert, M.J., Wright, R.D., Colson, Y.L. Nat. Med. (2000) [Pubmed]
  23. In vivo immunosuppression by targeting a novel protease receptor. Duchosal, M.A., Rothermel, A.L., McConahey, P.J., Dixon, F.J., Altieri, D.C. Nature (1996) [Pubmed]
  24. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. Nestel, F.P., Price, K.S., Seemayer, T.A., Lapp, W.S. J. Exp. Med. (1992) [Pubmed]
  25. The effect of graft-versus-host disease on T cell production and homeostasis. Dulude, G., Roy, D.C., Perreault, C. J. Exp. Med. (1999) [Pubmed]
  26. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. Hill, G.R., Teshima, T., Gerbitz, A., Pan, L., Cooke, K.R., Brinson, Y.S., Crawford, J.M., Ferrara, J.L. J. Clin. Invest. (1999) [Pubmed]
  27. Prevention of lethal murine graft versus host disease by treatment of donor cells with L-leucyl-L-leucine methyl ester. Charley, M., Thiele, D.L., Bennett, M., Lipsky, P.E. J. Clin. Invest. (1986) [Pubmed]
  28. Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. Cooke, K.R., Hill, G.R., Crawford, J.M., Bungard, D., Brinson, Y.S., Delmonte, J., Ferrara, J.L. J. Clin. Invest. (1998) [Pubmed]
  29. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. Reddy, P., Teshima, T., Kukuruga, M., Ordemann, R., Liu, C., Lowler, K., Ferrara, J.L. J. Exp. Med. (2001) [Pubmed]
  30. Interferon-gamma suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Krenger, W., Falzarano, G., Delmonte, J., Snyder, K.M., Byon, J.C., Ferrara, J.L. Blood (1996) [Pubmed]
  31. TNF receptor p55 controls early acute graft-versus-host disease. Speiser, D.E., Bachmann, M.F., Frick, T.W., McKall-Faienza, K., Griffiths, E., Pfeffer, K., Mak, T.W., Ohashi, P.S. J. Immunol. (1997) [Pubmed]
  32. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. Hill, G.R., Cooke, K.R., Teshima, T., Crawford, J.M., Keith, J.C., Brinson, Y.S., Bungard, D., Ferrara, J.L. J. Clin. Invest. (1998) [Pubmed]
  33. Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation. Hubbard, V.M., Eng, J.M., Ramirez-Montagut, T., Tjoe, K.H., Muriglan, S.J., Kochman, A.A., Terwey, T.H., Willis, L.M., Schiro, R., Heller, G., Murphy, G.F., Liu, C., Alpdogan, O., van den Brink, M.R. Blood (2005) [Pubmed]
  34. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Baker, J., Verneris, M.R., Ito, M., Shizuru, J.A., Negrin, R.S. Blood (2001) [Pubmed]
  35. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease. Maeda, Y., Levy, R.B., Reddy, P., Liu, C., Clouthier, S.G., Teshima, T., Ferrara, J.L. Blood (2005) [Pubmed]
  36. Total lymphoid irradiation nonmyeloablative preconditioning enriches for IL-4-producing CD4+-TNK cells and skews differentiation of immunocompetent donor CD4+ cells. Rigby, S.M., Rouse, T., Field, E.H. Blood (2003) [Pubmed]
  37. Altered T-cell receptor + CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-beta-treated alloreactive T cells that do not induce graft-versus-host disease. Boussiotis, V.A., Chen, Z.M., Zeller, J.C., Murphy, W.J., Berezovskaya, A., Narula, S., Roncarolo, M.G., Blazar, B.R. Blood (2001) [Pubmed]
  38. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Fontaine, P., Roy-Proulx, G., Knafo, L., Baron, C., Roy, D.C., Perreault, C. Nat. Med. (2001) [Pubmed]
  39. T cells require TRAIL for optimal graft-versus-tumor activity. Schmaltz, C., Alpdogan, O., Kappel, B.J., Muriglan, S.J., Rotolo, J.A., Ongchin, J., Willis, L.M., Greenberg, A.S., Eng, J.M., Crawford, J.M., Murphy, G.F., Yagita, H., Walczak, H., Peschon, J.J., van den Brink, M.R. Nat. Med. (2002) [Pubmed]
  40. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Ildstad, S.T., Sachs, D.H. Nature (1984) [Pubmed]
  41. Correction of enzyme deficiency in mice by allogeneic bone marrow transplantation with total lymphoid irradiation. Slavin, S., Yatziv, S. Science (1980) [Pubmed]
WikiGenes - Universities